Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000902664-25-001819
Filing Date
2025-04-16
Accepted
2025-04-16 16:56:31
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 10845
2 JOINT FILING AGREEMENT p25-0924exhibit99_1.htm EX-99.1 5427
  Complete submission text file 0000902664-25-001819.txt   18072
Mailing Address 72 CUMMINGS POINT ROAD STAMFORD CT 06902
Business Address 72 CUMMINGS POINT ROAD STAMFORD CT 06902 203-890-2000
Point72 Asset Management, L.P. (Filed by) CIK: 0001603466 (see all company filings)

EIN.: 465064661 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G

Mailing Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121
Business Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121 858-752-6170
Cidara Therapeutics, Inc. (Subject) CIK: 0001610618 (see all company filings)

EIN.: 461537286 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-88806 | Film No.: 25843394
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)